An AI-native biotechnology company building next-generation human vaccines and proprietary AI training datasets — where biology, data, and artificial intelligence converge.
Strategic Vision
Solving the "Unknown³" Problem
TeraVax Biotech addresses the compound uncertainty of biology, disease, and host–drug/vaccine interactions — the root cause of high costs and failure rates in drug and vaccine development. While many companies apply AI to noisy historical data, TeraVax Biotech generates its own high-quality, structured, prospectively designed datasets focused on human immunity.
With an initial emphasis on respiratory viruses and emerging zoonotic threats, the company's integrated biology–data–AI stack ensures every experimental cycle compounds the value of its strategic data assets.
A strategic collaboration with the University of North Carolina (UNC-CH) embeds ImmunAIsense into cutting-edge academic vaccinology, oncology, and translational immunology programs.
The UNC Collaboration Delivers
Access to human cohorts and mucosal models
Advanced respiratory and emerging pathogen expertise
Validation of antigen and biomarker hypotheses
High-fidelity immunological data for faster design–learn–redesign cycles
Market Signals
A Validated Market Opportunity
In January 2026, GSK and Noetik entered into significant licenses and acquisitions of AI training datasets from third-party biotech companies — including upfront fees of $50 million plus milestones — validating the commercial demand for high-quality immunological training data.
8+
Comparable Deals
Similar data licensing transactions completed over the past 3 years
$50M
Upfront Fees
Per deal in the GSK/Noetik benchmark transactions
2026
Market Inflection
Year of landmark AI training data deals signaling sector maturity
The ImmunAIsense platform is designed to generate high-quality training sets for both internal use and business development deals of this caliber.
Why Now
At the Intersection of Three Macro Trends
Clean Data for AI
Surging demand for high-quality, mechanistic immunological data to train next-generation AI disease models — a gap TeraVax Biotech is purpose-built to fill.
Flexible Vaccine Technologies
The global shift toward flexible, personalized vaccine platforms creates a premium market for modular, data-rich approaches like ImmunAIsense.
Privatization of Health Knowledge
The increasing privatization of the healthcare knowledge stack rewards companies that own proprietary data-generating engines — not just data consumers.
By owning the data-generating engine and embedding it in a strategic UNC collaboration, TeraVax Biotech ensures its competitive advantage grows with every vaccine developed and every study run on ImmunAIsense.
Commercial Model
Multi-Layered Revenue Strategy
TeraVax Biotech maximizes the value of its "biological operating system" through three complementary revenue streams — all strengthened by the UNC collaboration.
Internal Vaccine Pipeline
Developing high-value vaccine candidates for respiratory and emerging infections to reach clinical proof-of-concept, leveraging UNC expertise and clinical environments.
Pharma & Biotech Partnerships
Offering ImmunAIsense as a platform for external vaccine programs under fee-for-service, co-development, or shared-IP models — while retaining platform-level model improvements.
Data & AI Licensing
Licensing AI-driven tools and datasets for antigen design, regimen selection, and biomarker-based performance prediction as high-margin digital products.
The UNC collaboration serves as a demonstration site for pharma partners, enriches the AI training data foundation, and increases the translational value of the internal pipeline.
IP & Legal Foundation
Intellectual Property Protection
Exclusive License from MBF Therapeutics
TeraVax Biotech holds an exclusive license for the T-Max and ImmunAIsense platforms in human health, anchored by US Patent 11,130,787 (issued 9/28/2021) — covering DNA and RNA compositions to treat or prevent viral diseases and cancer in humans, livestock, and companion animals.
Global Patent Coverage
PCT application filed June 10, 2021 — International Search Report identified allowable claims
Qualified for Patent Prosecution Highway to accelerate global approvals
3rd-generation PCT claims filed in USA, Canada, UK, EU, and Australia
Investment Opportunity
Offering & Exit Strategy
Every vaccine developed and every collaborative study run on ImmunAIsense increases the strategic value of TeraVax Biotech — making it a compelling acquisition or partnership target as the platform matures.
Exit Pathways
Near-term: Partner with AI companies to expand disease training datasets
Mid-term: Partner with major pharmaceutical companies for development and commercialization of individual vaccine products after Phase I studies
Long-term: Acquisition of TeraVax Biotech by a major pharmaceutical company